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https://doi.org/10.1016/j.jacl.2019.06.0BACKGROUND: Cardiovascular disease (CVD) is a major cause of mortality and morbidity.
Increased low-density lipoprotein cholesterol (LDL-C) level is its major risk factor. Familial hypercho-
lesterolemia (FH) is a genetic disorder characterized by elevated LDL-C since birth and subsequent
premature CVD. There is a heterogeneity in the CVD onset in patients with FH. This is potentially
due to the presence of other independent risk factors. Lipoprotein(a) [Lp(a)] is an LDL-like particle
and represents a strong risk factor for CVD.
OBJECTIVE: Our objective was to understand the contribution of Lp(a) in the susceptibility to CVD
in individuals with genetic diagnosis of FH.
METHODS: We measured Lp(a) levels in 2 independent and well-characterized genetic-FH cohorts:
the FH-Gothenburg cohort (n5 190) and the FH-CEGP Milan cohort (n5 160). The genetic diagnosisulting for Amgen, Sanofi-Aventis,
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2 Journal of Clinical Lipidology, Vol -, No -, - 2019was performed by targeted next-generation sequencing (FH-Gothenburg and part of the FH-CEGP Mi-
lan cohort), or by Sanger sequencing.
RESULTS: We show that among individuals with genetic diagnosis of FH, those with previous CVD
had higher Lp(a) levels. In addition, analyzing the response to the lipid-lowering therapies, we have
also shown that statins had the same LDL-C–lowering effect irrespective of the type of FH-
causative mutation. However, when we examined the lipid-lowering effect of proprotein convertase
subtilisin/kexin type 9 inhibition by antibodies, we observed a trend in a better reduction of the
LDL-C level in carriers of nonsense mutations.
CONCLUSION: In conclusion, our results suggest that Lp(a) contributes to CVD onset in individuals
with genetic diagnosis of FH. Our finding supports the importance to identify an efficacious therapy to
lower Lp(a) in patients with FH to prevent CVD onset or recurrence.
 2019 National Lipid Association. Published by Elsevier Inc. This is an open access article under the CC
BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Cardiovascular disease (CVD) is a major cause of
mortality and morbidity in Western Countries. Increased
low-density lipoprotein cholesterol (LDL-C) level is a
major risk factor for CVD1 and thus one of the main target
for its prevention.2
Familial hypercholesterolemia (FH) is a genetic in-
herited disorder mainly caused by mutations in genes
encoding for the LDL receptor (LDLR), apolipoprotein B
(APOB, the main protein of LDL) or proprotein convertase
subtilisin/kexin type 9 (PCSK9).3 FH is characterized by
elevated LDL-C since birth and subsequent premature
CVD development.4 Statins represent the pivotal LDL-C–
lowering drug in individuals with FH to prevent CVD.
However, the efficacy of statins in FH shows high individ-
uals variability.5 Despite the strong penetrance of the dis-
ease, there is a heterogeneity in the onset of CVD in
patients with FH. This is potentially due to differences in
the response to lipid-lowering therapy or to the presence
of other independent risk factors including high levels of
lipoprotein(a) [Lp(a)].
Lp(a) (or LPA) is an LDL-like particle synthetized by
the liver and consists of an APOB-100 covalently linked to
a very large glycoprotein known as apolipoprotein(a).
Circulating Lp(a) levels are predominantly controlled by
genetic variations on the LPA gene6 and seem not to be
changed by diet, physical activity or other environmental
factors.7,8 To date, Lp(a) is not effectively lowered by any
approved drugs. However, novel therapeutic drugs able to
lower Lp(a) are currently under clinical trials.9–11
Lp(a) represents a strong risk factor for CVD.12 Mende-
lian randomization studies with genetic variables primarily
increasing Lp(a) have shown that high Lp(a) is an indepen-
dent risk factor for CVD in the general population indepen-
dently from the other traditional risk factors including
LDL-C.13–15 However, the role of Lp(a) in CVD prevalence
in patients with FH is still a matter of debate. Previous
studies described higher Lp(a) levels in patients with FH
with previous CVD. However, most of these studies were
performed in patients with diagnosis of FH established
using clinical evidence and not confirmed by genetictests.16–19 Alonso et al in 2014 showed that individuals
with genetic diagnosis of FH had higher Lp(a) than their
unaffected relatives.20 They have also shown that among
the individuals with genetic diagnosis of FH, those with
CVD had higher Lp(a) than those without previous CVD
events. Furthermore, they showed that individuals with a
nonsense mutation in the LDLR had higher Lp(a) and
higher CVD incidence than those with missense mutation
on the same gene. However, in this very elegant study,
the genetic diagnosis of FH was performed using a micro-
array containing only a selection of mutations in LDLR and
of different mutations in APOB. In addition, only selected
mutations (namely the most frequent null and defective mu-
tations) on the LDLR were included in the analysis stratified
by type of mutation.
Here, to understand the contribution of Lp(a) in the
susceptibility to CVD, we performed a comprehensive
genetic diagnosis of FH using targeted next-generation
sequencing of the main FH-causative genes namely LDL-R,
APOB, and PCSK9 in individuals from two European Lipid
Clinics. We show that among individuals with definite ge-
netic diagnosis of FH, those with previous CVD had higher
circulating levels of Lp(a) in these 2 independent cohorts.
Analyzing the response to the lipid-lowering therapies,
we have also shown that statins had the same LDL-C–
lowering effect irrespective of the type of mutation
(nonsense vs missense) in both FH study cohorts. However,
when we examined the lipid-lowering effect of PCSK9 in-
hibition by antibodies, we observed a trend in a better
reduction of the LDL-C level in carriers of nonsense
mutations.Materials and methods
Study cohorts
The FH-Gothenburg cohort
In the present study, we included 190 adult individuals
with genetic diagnosis of FH from the Lipid Clinic,
Department of Cardiology, Sahlgrenska University Hospital
Pavanello et al Lp(a) is a strong CVD risk factor in FH 3in Gothenburg, Sweden. At the time of the first visit, all the
individuals underwent a physical and clinical examination.
Clinical profile (including lipid profile, liver panel, and
other biochemical parameters) was determined in freshly
isolated 12-hours fast plasma or serum at the Department of
Clinical Chemistry, Sahlgrenska University Hospital, as
previously described.21 LDL-C after lipid-lowering therapy
(namely treated LDL-C) refers to the LDL-C level at the
last available assessment. The diagnosis of CVD was per-
formed based on the presence of previous myocardial
infarction or stroke (self-reported or present in personal re-
ports). Individuals referred to the lipid clinic for genetic
diagnosis have had a myocardial infarction . 5 months
ahead of the visit and therefore not in an acute state.
All subjects gave their written informed consent to
participate in the study. The study was approved by the
regional ethics committee of Gothenburg.
The FH-CEGP Milan cohort
We included 168 adult subjects with genetic diagnosis of
FH from the Dyslipidemia Center ‘‘E. Grossi Paoletti’’ of
ASST Grande Ospedale Metropolitano Niguarda, Milan,
Italy. At the time of the first visit, all the individuals
underwent a physical and clinical examination. Biochem-
ical profile was determined after at least 1 month of lipid-
lowering treatment suspension in freshly isolated 12-hour
fast plasma or serum as previously described.22 LDL-C af-
ter lipid-lowering therapy (namely treated LDL-C) refers to
the LDL-C level at the last available assessment. Cardio-
vascular events were defined as previous diagnosis of
angina, acute myocardial infarction, stroke, and peripheral
arterial disease. All subjects gave their written informed
consent to use their clinical data for the study, which was
approved by the ethics committee of ASST Grande Ospe-
dale Metropolitano Niguarda, Milan, Italy (approval no
19-022016).
Genetic diagnosis of FH
For the FH-Gothenburg cohort, the genetic diagnosis of
FH was performed by targeted next-generation sequencing
as previously described.21 Specifically, DNA was isolated
from whole blood. Targeted next-generation sequencing
was performed using SEQPRO LIPO RS (Progenika Bio-
pharma, Derio, Spain, http://www.progenika.com/) (for
the first 165 samples) or using SEQPRO LIPO IS (Proge-
nika Biopharma, Derio, Spain, http://www.progenika.com/)
(the remaining samples). The exons and their flanking re-
gions of LDLR, APOB (exon 26 and 29), PCSK9, and low-
density lipoprotein receptor adaptor protein 1 (LDLRAP1),
or of LDLR, APOB, PCSK9, LDLRAP1, apolipoprotein E
(APOE, exon 4), and signal-transducing adaptor protein 1
(STAP1) were sequenced using SEQPRO LIPO RS or by
SEQPRO LIPO IS, respectively.
For the FH-CEGP Milan cohort, the genetic diagnosis of
FH was performed by Sanger sequencing (first 90 cases) or
by targeted next-generation sequencing (the remainingsamples) within the LIpid TransPort Disorders Italian
GEnetic Network (LIPIGEN) project.23
Plasma Lp(a) measurements
For the FH-Gothenburg cohort, fasting plasma samples
were collected at time of enrollment and stored at 280C.
Lp(a) levels were then measured on all samples simulta-
neously (on April 2018) by immunoturbidimetric assay
(Randox laboratory, United Kingdom) using an ABX
Pentra400 (Horiba, Japan) analyzer. The precision of the
Randox assay has been determined at 2 levels in an in-
house verification: 1) at the 0.19 g/L level, a total coeffi-
cient of variance (CV) of 2.4% was determined and 2) at
the 0.50 g/L level, a total CV of 1.6% was determined. For
the present analysis, Lp(a) measurements below the assay
detection limit were considered equal to the lower detection
limit (10 mg/dL).
For the FH-CEGP Milan cohort, Lp(a) levels were
measured on freshly isolated fasting plasma samples at
the time of enrollment (since 2015) using the immunotur-
bidimetric assay (Tina-quant Lipoprotein (a) Gen.2, Roche
Diagnostics, Switzerland) using a Cobas c311 autoanalyzer.
All samples of this cohort were measured using the same
assay. The precision of the Roche assay has been deter-
mined in a total CV of 1.7% for 40.7 nmol/L level and a
total CV of 1.2% for 156 nmol/L level.
To evaluate the assay agreement between the different
methods, a subset of plasma samples (N 5 27) from the
Gothenburg cohort, was aliquoted, refrozen, and analyzed
both in Milan using the Roche assay and in Gothenburg
using the Randox assay. The samples were chosen to get a
representation of the whole measurement range. The result
from this method comparison is presented in Supplement
Figure 1.
Statistical analysis
For descriptive statistic, continuous traits are shown as
mean and standard deviation or as median and interquartile
range. Categorical traits are shown as number and propor-
tion. For continuous traits, P-value was calculated by linear
regression unadjusted, or adjusted for age, gender, and BMI
when appropriate. Non-normally distributed values were
log-transformed before entering the model. For categorical
traits, P-value was calculated by chi-square or by Fisher-
exact test as appropriate. Lp(a) levels in patients with FH
for the FH-CEGP Milan cohort stratified by CVD status
were compared using one-tailed T-test. For assays agree-
ment evaluation, a Bland–Altman plot was generated. To
evaluate correlation between the 2 methods, results from
the Gothenburg method were plotted against results from
the Milan method, a regression line was fitted, and both
the Pearson and the Spearman correlation coefficients
were calculated. Statistical analyses were performed using
the IBM Statistical Package for Social Sciences (IBM
SPSS, version 20.0, Inc. Chicago, IL) and GraphPad
Table 1 Characteristics of patients with FH from Gothenburg
4 Journal of Clinical Lipidology, Vol -, No -, - 2019Prism7.02. P-values ,.05 were considered statistically
significant.Trait FH Gothenburg
N 190
Women/Men, n (%) 92/95 (49/51)
Homozygosity, compound heterozygosity,
or double heterozygosity, n (%)
7 (4)
Age, y 46 6 15
BMI, kg/m2 26 6 4
Xanthomas, n (%)* 21 (21)
Xanthelasmas, n (%) -
Arcus cornealis, n (%)† 8 (8)
Cardiovascular disease, n (%)‡ 61 (43)
Active smoking, n (%) 14 (7)
Hypertension, n (%) 19 (10)
Diabetes, n (%) 6 (3)
Plasma lipids
Total cholesterol, mg/dL 383 6 78
Triglycerides, mg/dL 79 (72–141)
LDL-C, mg/dL 299 6 68
HDL-C, mg/dL 55 6 16
Treated LDL-Cx, mg/dL 141 6 69
Lp(a), mg/dL 24 (10–56)
Liver panel
AST, U/L 27 (22–34)
ALT, U/L 32 (23–45)
g-GT, U/L -
Total bilirubin, mg/dL -
Other biochemical parameters
Creatinine kinase, U/L 112 (76–170)
Uric Acid, mg/dL -
Glucose, mg/dL 100 6 12
Insulin, mIU/L 9.2 (6.3–14)
HOMA-IR, U 2.2 (1.7–3.7)
Lipid medications
Statin use, n (%)ǁ 105 (85)
PCSK9 mAbs use, n (%) 13 (7)
Gene
LDL-R 178 (93.7)
APOB 9 (4.7)
PCSK9 2 (1.1)
STAP1 1 (0.5)
Pathogenicity
N 180
Pathogenic 144 (80)
Possibly pathogenic 22 (12)
Probably pathogenic 4 (2)
Unknown# 10 (6)
BMI, body mass index; LDL-C, low-density lipoprotein cholesterol;
HDL-C, high-density lipoprotein cholesterol; AST, aspartate aminotrans-
ferase; ALT, alanine aminotransferase; g-GT, gamma-glutamyltransferase;
HOMA-IR, homeostatic model assessment; PCSK9 mAbs, proprotein
convertase subtilisin kexin type 9 monoclonal antibodies.
Data are expressed as mean (6SD) or as number (proportion) as
appropriate. Lipid profile was measured before starting any treatment.
*Data on xanthomas available for N 5 101.
†Data on arcus cornealis available for N 5 95.
‡Data on cardiovascular disease available for N 5 141.
xTreated LDL-C at last available assessment.
ǁData on statin use available for N 5 123.
#The totality of mutation classified as of unknown pathogenicity
were detected on LDLR.Results
Characteristics of the FH-Gothenburg cohort
A total of 190 individuals with genetic diagnosis of FH
from the lipid clinic, Department of Cardiology, Sahlgren-
ska University Hospital in Gothenburg, Sweden (namely
FH-Gothenburg cohort) were examined. The characteristics
of the participants are shown in Table 1. Briefly, individuals
were all adults (mean age 46 6 15 years) with mean BMI
26 6 4 kg/m2, mean LDL-C level before treatment
299 6 68 mg/dL, and median current Lp(a) levels 24
(10–56) mg/dL. Fifty-one percent of them were men,
10% had hypertension, 3% had diabetes, and 7% were
active smokers. Most of the cohort was under statin treat-
ment (85%), whereas 7% (n 5 13) was under PCSK9
mAbs treatment alone or in combination with statin (10/
13 were treated with PCSK9 mAbs plus statins, 3/13 with
PCSK9 mAbs only). Among the 190 genetic-FH patients,
61 had personal history of CVD events (43%) defined as
previous stroke or myocardial infarction. Most individuals
from the FH-Gothenburg cohort were carriers of mutation
in LDLR gene (93.7%, n 5 178), 4.7% (n 5 9) were car-
riers of mutations in APOB, and only a minority of them
were carriers of mutations in PCSK9 (n 5 2) or STAP1
(n 5 1) (1.1 and 0.5%, respectively). Most of the individ-
uals of the FH-Gothenburg cohort were carriers of muta-
tions previously described as FH-causative (80% were
carriers of mutations described as pathogenic, 12% possibly
and 2% probably pathogenic). In addition to these, we de-
tected 7 new mutations with unknown pathogenicity (not
previously described as FH-causative mutations) in 10 indi-
viduals (6%). The totality of these mutations was detected
on the LDLR. Specifically, we identified 2 mutations in
splicing sites, 1 in-frame deletion, and 4 different amino
acid changes (accounting for the 57% on the individuals
with mutation of unknown pathogenicity) (Supplementary
Table 1).
Individuals with genetic diagnosis of FH and
previous CVD have higher Lp(a) levels in the FH-
Gothenburg cohort
To test whether individuals with genetic-FH and previ-
ous CVD had higher Lp(a), we examined the differences in
the clinical characteristics of the study participants strati-
fied by CVD status. We found that individuals with
previous CVD had approximately 2-fold increased Lp(a)
levels compared with those without CVD (P 5 .037,
Fig. 1A). Importantly, we did not detect differences in the
untreated or in the treated LDL-C comparing these 2 groups
(Fig. 1B). These data suggest that Lp(a) is a risk factor for
Figure 1 Patients with FH with previous cardiovascular disease events have higher circulating level of Lp(a) in the FH-Gothenburg
cohort. Plasma levels of (A) Lp(a) and (B) untreated and treated LDL-C in patients with FH from the Gothenburg cohort stratified by car-
diovascular status. Data expressed as median and quartile range or as mean and SD as appropriate. P value has been calculated by linear
regression unadjusted. Non-normally distributed traits were log-transformed before entering the model. Lp(a), lipoprotein(a).
Pavanello et al Lp(a) is a strong CVD risk factor in FH 5CVD in patients with FH even stronger than LDL-C. No
differences in age, gender, hypertension, or smoking were
found between the 2 groups (Supplementary Table 2). How-
ever, genetic-FH individuals with previous CVD had higher
BMI (28 6 5 kg/m2 vs 26 6 4 kg/m2, P 5 .031) and higher
prevalence of diabetes (10% vs 0%, P 5 .003). In addition,
the proportion of individuals under statin therapy was
higher in genetic-FH individuals with CVD than in those
without previous CVD.
The response to lipid-lowering therapy does not
differ between genetic-FH patients with
nonsense or missense mutations in the FH-
Gothenburg cohort
To test whether the response to lipid-lowering therapy
was different in genetic-FH with nonsense or missense
mutations, we firstly examined the absolute and relative
LDL-C reduction in the overall FH-Gothenburg cohort
stratified by type of mutation. Individuals homozygous for
FH-mutations were excluded from the analysis. We found
that there were no differences between individuals with
nonsense or missense mutations in the absolute nor in the
relative LDL-C in the overall FH-Gothenburg cohort
(Fig. 2A and B).
Then we examined the absolute and relative LDL-C
reduction in individuals after statin or PCSK9 mAbsFigure 2 The response to lipid-lowering therapy does not differ betwee
Gothenburg cohort. (A) Absolute and (B) relative LDL-C reduction acco
cohort. Data are expressed as mean6 SD. P value calculated by linear re
under statin and PCSK9 mAbs treatment. Individuals homozygous for F
density lipoprotein cholesterol; FH, familial hypercholesterolemia; PCStherapy separately. We found that there were no differences
in the absolute or in the relative LDL-C reduction after
statin therapy based on the type of mutation. When we
examined the response to the PCSK9 mAbs therapy (alone
or in combination with statin), we found a slightly higher
absolute and relative LDL-C reduction in individuals with
nonsense compared to those with missense mutations
suggesting a better response to PCSK9 mAbs therapy in
individuals with nonsense mutation. However, this slight
difference was not significant. No differences in the
anthropometric traits or in CVD, active smoking, hyper-
tension, or diabetes prevalence were found between the 2
groups. However, individuals with nonsense mutation had a
more severe phenotype with higher prevalence of tendon
xanthomas, and higher total cholesterol and untreated LDL-
C (Supplementary Table 3). In addition, the proportion of
individuals under statin therapy was higher in carriers of
nonsense than in carriers of missense mutation.
Lp(a) is a risk factor for CVD in individuals with
genetic diagnosis of FH and the type of FH
mutation does not affect the response to statin
therapy in an independent genetic-FH cohort
To confirm our finding in the FH Gothenburg cohort, we
used an independent genetic-FH cohort from Milan, Italy
(namely FH CEGP Milan cohort). A total of 168n patients with FH with nonsense or missense mutations in the FH
rding to type of mutations in patients with FH from the Gothenburg
gression unadjusted. A total of 10 FH patients were simultaneously
H mutations have been excluded from the analysis. LDL-C, low-
K9, proprotein convertase subtilisin/kexin type 9.
Table 2 Characteristics of patients with FH from FH-CEGP
Milan cohort
Trait FH CEGP Milan
N 168
Women/men, n (%) 68/100 (40/60)
Homozygosity, compound heterozygosity,
or double Heterozygosity, n (%)
7 (4.2)
Age, y 39 6 17
BMI, kg/m2 24 6 4
Xanthomas, n (%)* 95 (59)
Xanthelasmas, n (%) 14 (8)
Arcus cornealis, n (%)† 44 (27)
Cardiovascular disease, n (%) 39 (23)
Active smoking, n (%) 24 (14)
Hypertension, n (%) 33 (20)
Diabetes, n (%) 7 (4)
Plasma lipids
Total cholesterol, mg/dL 394 6 85
Triglycerides, mg/dL 114 (79–155)
LDL-C, mg/dL 316 6 82
HDL-C, mg/dL 51 6 14
Treated LDL-C‡, mg/dL 162 6 69
Lp(a), mg/dL 21 (6–51)
Liver panel
AST, U/L 20 (17–26)
ALT, U/L 20 (15–28)
g-GT, U/L 16 (12–25)
Total bilirubin, mg/dL 0.63 (0.44–0.93)
Other biochemical parameters
Creatinine kinase, U/L 109 (75–164)
Uric acid, mg/dL 4.9 6 1.3
Glucose, mg/dL 87 6 18
Insulin, mIU/L -
HOMA-IR, U -
Lipid medications
Statin use, n (%)x 92 (67)
PCSK9 mAbs use, n (%) 26 (15)
Gene
LDL-R 168 (100)
APOB
PCSK9 -
STAP1 -
Pathogenicity
N 168
Pathogenic 156 (93)
Possibly pathogenic 6 (4)
Probably pathogenic 2 (1)
Unknownk 4 (2)
BMI, body mass index; LDL-C, low-density lipoprotein cholesterol;
HDL-C, high-density lipoprotein cholesterol; AST, aspartate aminotrans-
ferase; ALT, alanine aminotransferase; g-GT, gamma-glutamyltransferase;
HOMA-IR, homeostatic model assessment; PCSK9 mAbs, proprotein
convertase subtilisin kexin type 9 monoclonal antibodies.
Data expressed as mean (6SD), median and quartile range or as
number (proportion) as appropriate. Lipid profile was measured before
starting any treatment.
*Data on xanthomas available for N 5 162.
†Data on arcus cornealis available for N 5 162.
‡Treated LDL-C at last available assessment.
xData on statin use available for N 5 140.
kThe totality of mutation classified as of unknown pathogenicity
were detected on LDLR.
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mia Center ‘‘E. Grossi Paoletti’’ ASST Grande Ospedale
Metropolitano Niguarda were included in the present study.
Anthropometric, clinical, and biochemical characteristics
of the FH CEGP Milan cohort are shown in Table 2. Briefly,
60% of them were men, 20% had hypertension, and 4% had
diabetes. When we compared the 2 independent cohorts, we
found that individuals from the FH-CEGP Milan cohort
were younger (39 6 17 years vs 46 6 15, P , .0001),
with lower BMI (24 6 4 kg/m2 vs 26 6 4 kg/m2,
P 5 .002), and with a better liver and glucose profile
(Supplementary Table 4). However, individuals from the
FH-CEGP Milan cohort had a more severe phenotype
with higher prevalence of tendon xanthomas and arcus cor-
nealis, and with higher levels of total cholesterol, LDL-C
(both untreated and treated LDL-C), and Lp(a). The propor-
tion of individuals under statin therapy and the prevalence
of CVD were lower in the FH-CEGP Milan cohort, whereas
the number of individuals under PCSK9 mAbs therapy was
higher than the FH-Gothenburg cohort. For Lp(a) measure-
ments, we have evaluated the assay agreement between the
2 methods and, lack of uniformity was demonstrated
(Supplementary Fig. 1). Nevertheless, both assays per-
formed sufficiently well to demonstrate the association of
Lp(a) with CVD in the respective cohorts.
To confirm our finding on the increased Lp(a) levels in
genetic-FH with previous CVD, we examined the differ-
ences in the clinical characteristics of the FH-CEGP Milan
cohort stratified by CVD status. Consistently with our
results in the FH-Gothenburg cohort, we found that in-
dividuals with previous CVD had approximately 2-fold
increased Lp(a) levels compared with those without CVD
(one-tailed P 5 .045, Fig. 3A) in the FH-CEGP Milan
cohort. Importantly, we did not detect differences in the un-
treated nor in the treated LDL-C comparing these 2 groups
(Fig. 3B).In the FH-CEGP Milan cohort, genetic-FH indi-
viduals with previous CVD were older, with a higher
BMI, and higher prevalence of hypertension than those
without previous CVD (Supplementary Table 5). In addi-
tion, HDL level and the proportion of active smokers
were lower in individuals with previous CVD than in those
without. No other differences in biochemical traits were de-
tected between the 2 groups.
These results support our findings in FH-Gothenburg
cohort and confirm Lp(a) as risk factor for CVD in
individuals with genetic diagnosis of FH.
To confirm that the response to lipid-lowering therapy
does not differ between genetic-FH patients with nonsense
or missense mutations, we examined the absolute and
relative LDL-C reduction in the FH-CEGP Milan cohort
stratified by type of mutation. Individuals homozygous for
FH mutations were excluded from the analysis. We found
that there were no differences between individuals with
nonsense or missense mutations in the absolute nor in the
relative LDL-C in the overall FH-CEGP Milan cohort
(Fig. 4A and B). The same result was obtained when only
individuals under statin therapy were analyzed. When we
Figure 3 Patients with FH with previous cardiovascular disease events have higher circulating level of Lp(a) in the FH CEGP Milan
cohort. Plasma levels of (A) Lp(a) and (B) untreated and treated LDL-C in FH patients from the CEGP Milan cohort stratified by cardio-
vascular status. Data expressed as median and quartile range or as mean and SD as appropriate. P value has been calculated by one-tailed
T-test. Non-normally distributed traits were log-transformed before entering the model. Lp(a), lipoprotein(a); LDL-C, low-density lipopro-
tein cholesterol; FH, familial hypercholesterolemia.
Pavanello et al Lp(a) is a strong CVD risk factor in FH 7examined the response to the PCSK9 mAbs therapy, we
found a slightly higher and borderline significant relative
LDL-C reduction in individuals with nonsense compared
with those with missense mutations (Fig. 4B, P 5 .044).
The same trend was observed in the absolute LDL-C reduc-
tion although not significant. No other differences between
the 2 groups were detected except for higher prevalence of
active smokers and higher Lp(a) levels in individuals with
nonsense than in those with missense mutation
(Supplementary Table 6). These results support our finding
in the FH-Gothenburg cohort and suggest that the type of
FH mutation does not affect the response to statin therapy.
However, it seems that individuals with nonsense mutations
have a better response to PCSK9 mAbs therapy resulting in
a higher relative LDL-C reduction.Discussion
In this work, we show that individuals with genetic
diagnosis of FH and previous cardiovascular events have
higher Lp(a) levels than those without CVD in 2 indepen-
dent cohorts. Lp(a) is an independent risk factor for
CVD24–28 and high levels of this lipoprotein may contribute
to the variability of the onset of CVD observed in individ-
uals with FH. Our result is in line with previous findingFigure 4 The response to lipid-lowering therapy does not differ betwe
exception for the PCSK9 mAbs) in the FH CEGP Milan cohort. (A) Ab
tations in patients with FH from the Gothenburg cohort. Data are expre
justed. Individuals homozygous for FH mutations have been excluded fro
9; LDL-C, low-density lipoprotein cholesterol; FH, familial hypercholedescribing higher Lp(a) in individuals with genetic diag-
nosis of FH and previous CVD events.20,29 In these studies,
the genetic diagnosis of FH was performed using microar-
ray containing a selection of mutations in LDLR or
APOB,30 or by unspecified DNA tests.29 In the present
study, we examined Lp(a) levels in 2 independent cohorts
in which the genetic diagnosis of FH has been performed
by targeted next generation sequencing or Sanger
sequencing. Specifically, in the FH-Gothenburg cohort,
we performed genetic diagnosis of FH by screening
comprehensively the main FH-causative genes (namely,
LDLR, APOB, PCSK9, and LDLRAP1, or LDLR, APOB,
PCSK9, LDLRAP1, APOE, and STAP1). In this cohort,
93.7% of the individuals with genetic diagnosis of FH
were carriers of mutation on LDLR; 4.7% were carriers of
mutations on APOB; and only a minority of them were car-
riers of mutations on PCSK9 or STAP1 (1.1 and 0.5%,
respectively). We identified 2 individuals homozygote for
LDLR mutation (LDLR p.Gly505Asp, or LDLR
p.Glu408Lys), one compound heterozygote (carrying the
LDLR p.Ser637Cys and LDLR p.Asn665Lys), and 4
double heterozygote (LDLR p.Cys296*plus PCSK9 p.Ar-
g46Leu; LDLR p.Cys261Phe plus PCSK9 c.524-4A.G,
LDLR c.2390-2A.G plus APOB p.Arg3527Gln, and
APOB p.Arg3527Gln plus PCSK9 p.Arg46Leu). Most of
the individuals were carriers of mutations previouslyen patients with FH with nonsense or missense mutations (with the
solute and (B) relative LDL-C reduction according to type of mu-
ssed as mean 6 SD. P value calculated by linear regression unad-
m the analysis. PCSK9, proprotein convertase subtilisin/kexin type
sterolemia.
8 Journal of Clinical Lipidology, Vol -, No -, - 2019described as pathogenic, possibly pathogenic or probably
pathogenic (80, 12, and 2%, respectively). In addition,
our unbiased approach allowed us to detect 7 novel muta-
tions (not previously described in patients with FH) in 10
(6%) individuals from the FH-Gothenburg cohort. Of the
7 novel mutations, 5 where resulting in an amino acidic
change, 1 in an in-frame deletion, and 1 occurred in a
splicing site. Pathogenicity of these mutations should be
confirmed.
In the FH-CEGP Milan, the genetic diagnosis of FH was
performed using Sanger sequencing of LDLR gene (the first
90 patients), or by targeted next generation sequencing of
LDLR, APOB, PCSK9, and LDLRAP1. This difference in
sequencing methods in the FH-CEGP Milan cohort does
not affect the FH diagnosis reliability. However, the
comprehensive screening of the main FH-causative genes
increases the diagnosis rate and allows the identification
of new possible causative mutations. For these reasons,
we switched from Sanger sequencing to next generation
sequencing to perform the FH genetic diagnosis also in
the FH-CEGP Milan cohort. In this cohort, all the individ-
uals were carriers of mutation on the LDLR. Of these indi-
viduals, 2 were double heterozygous carrying additional
mutations on APOB or on PCSK9 (LDLR p.Arg350* plus
PCSK9 p.Asp50Asp; LDLR p.Gly343Ser plus APOB
p.Thr3826Met plus PCSK9 p.Ala30Gly; LDLR Cy-
s222_Asp227dup plus APOB Thr3754Ile 1 Thr2749Ala).
In addition, 2 novel mutations in 2 subjects have been de-
tected in the FH-CEGP cohort. One is a duplication of
the nucleotide 1125 that results in a frameshift mutation
(p.Lys376Glnfs*5), and one is an intronic deletion that af-
fects a splicing site (c.1587-2delA). Pathogenicity of these
mutations should be confirmed as well.
In both FH-Gothenburg and Milan cohorts, the diagnosis
of CVD was performed based on the presence of previous
myocardial infarction or stroke. Lp(a) levels were measured
by turbidimetric assays performed using frozen plasma or
freshly isolated plasma for FH-Gothenburg and Milan,
respectively. We have evaluated the assay agreement
between the 2 methods and demonstrated a lack of
uniformity. Despite the differences in Lp(a) measurement
methods between the 2 cohorts, we detected 2-fold higher
Lp(a) levels in FH individuals with CVD than in those
without CVD in both cohorts. This finding was consistent
in the 2 independent cohorts, suggesting that the final
finding is comparable between the 2 cohorts and not
affected by the type (frozen or fresh) of samples used for
the measurements. However, variation due to assay meth-
odology could affect risk assessment in individual patients,
accentuating the need to improve calibration and standard-
ization of Lp(a) assays.31
The same 2-fold increase in Lp(a) that we detected in
individuals with previous CVD, was detected by Alonso
et al in individuals with genetic diagnosis of FH and
CVD.20 Nenseter et al, detected a 3-fold increased Lp(a)
levels in individuals with genetic diagnosis of FH suscepti-
ble to CVD (with premature CVD) compared with thoseCVD resistant (later or no CVD).29 Very recently, Ellis
et al showed that the combined presence of high Lp(a)
and FH confers 5.3-fold increased risk of premature
CAD, compared with a 1.9-fold and 3.2-fold increase due
to the presence of the 2 factors separately.32 All together
these findings strongly suggest that Lp(a) is a risk factor
for CVD in individuals with genetic diagnosis of FH.
When we looked at other clinical characteristics of the
individuals with genetic diagnosis of FH stratified based on
the CVD status, we observed that those with previous CVD
event had higher classical CVD risk factors, namely
diabetes, hypertension, and BMI, but we did not detect
any difference in smoking status. This is consistent with a
previous report on 1690 individuals with clinical diagnosis
of FH in which those with previous CVD events had higher
classical CVD risk factors with the exception of smoking.33
When we stratified the FH cohorts based on type of
mutation (nonsense vs missense mutation), we found that
individuals with nonsense mutation had an overall more
severe phenotype (namely, higher total cholesterol, and
LDL-C) in FH Gothenburg with similar trend in FH
Milano. This is consistent with the possible presence of
residual LDLR activity in missense mutations, which may
mitigate the FH phenotype. In other words, nonsense
mutations induce a complete loss of function of LDLR
and may result in a more severe phenotype; missense
mutations alter LDLR activity without inducing a complete
loss of function. This results in a possible presence of
residual LDLR activity in missense mutations, which may
mitigate the FH phenotype.
In addition, we observed that individuals carrying
nonsense mutations had higher Lp(a) levels than those
carrying missense mutations in the FH CEGP Milan cohort
(with a similar but not significant trend in the FH
Gothenburg). It has been proposed that LDLR mutations
result in high Lp(a) levels with a gene-dosage effect.34
Alonso et al showed that Lp(a) levels were higher in indi-
viduals with LDLR null allele than in those with defective
allele.20 In this study, only the most prevalent null and
defective mutations on the LDLR were included in the anal-
ysis. Here we extend these findings in 2 independent co-
horts (one from Sweden and one from Italy) by a
comprehensive analysis of all the nonsense or missense mu-
tations detected on the sequenced genes. Considering that
most individuals from our 2 cohorts were carriers of muta-
tions on the LDLR, our results together with previous data
support the role of LDLR in Lp(a) circulating levels
although the mechanisms remain still known.
When we looked at the response to lipid-lowering
therapies, we found the same lowering effect of statins
irrespective of the type of mutation in both FH cohorts. The
efficacy of statins in FH shows high interindividual
variability.5 It has been proposed that this variability may
be a function of the type of FH-causative mutation. Previ-
ous studies investigated this hypothesis with conflicting re-
sults. Most of these studies, consistently with our results,
detected similar response to statins irrespective of the
Pavanello et al Lp(a) is a strong CVD risk factor in FH 9type of mutation.35–39 However, other studies described a
better response to statins in individuals with more delete-
rious mutations (null allele) than individuals with milder
mutations (defective allele),40–43 and few studies, on the
contrary, reported a better response to statins in individuals
with mild mutations compared with individuals with delete-
rious mutations.44,45 All these previous studies examined
the response to weak statins (mostly fluvastatin and simva-
statin) stratified by type of mutation of only the LDLR gene.
In the present study, we examined the response to stronger
statins (atorvastatin and rosuvastatin). In addition, we
extended the analysis not only at the LDLR mutations but
also to all the nonsense or missense mutations detected in
LDLR, APOB, PCSK9, and STAP1 gene.
Moreover, for the first time to our knowledge we
examined the lipid-lowering efficiency of PCSK9 inhibition
stratified by type of mutation. We observed a trend in a
better reduction in the LDL-C in carriers of nonsense
mutations under anti-PCSK9 treatment alone (FH-Milan
cohort) or in combination with statins (FH-Gothenburg
cohort). These results need confirmation on larger numbers
of patients treated with PCSK9 inhibition.
In conclusion, our results suggest that Lp(a) contributes
to CVD onset in individuals with genetic diagnosis of FH.
Our finding supports the importance to identify an effica-
cious therapy to lower Lp(a) in patients with FH to prevent
CVD onset or recurrence.Acknowledgments
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Pavanello et al Lp(a) is a strong CVD risk factor in FH 10.e1AppendixSupplementary Table 1 Description of the mutations of unknown pathogenicity in the LDLR gene from the FH-Gothenburg cohort
(Ref Seq NM_000527.4)
N (%)* Exon Nucleotide change Amino acid change Type
1 (5) 6 c.940_940114del15 NA SPLICING
2 (10) 7 c.1012T.G Cys338Gly AC
2 (10) 8 c.1174T.C Cys392Arg AC
1 (5) 9 c.1187-7C.A NA SPLICING
2 (10) 10 c.1514G.A Gly505Asp AC
1 (5) 12 c.1754T.C Ile585Thr AC
1 (5) 13 c.1871_1873delTCA Ile624del IN-FRAME INDEL
Cys, cysteine; Gly, glycine; Arg, arginine; NA, not available; Trp, tryptophan; Asp, aspartate; Ile, isoleucine; Thr, threonine; del, deletion; Gln,
glutamine.
*Proportion was calculated on the N 5 20 total number of individuals with mutation classified as of unknown pathogenicity.
Supplementary Table 2 Characteristics of patients with FH from the FH-Gothenburg cohort stratified by cardiovascular disease status
Trait
FH Gothenburg
P valueCVD negative CVD positive
N 80 61
Women/men, n (%) 42/37 (53/47) 25/36 (41/59) .154
Homozygosity, compound heterozygosity or
double heterozygosity, n (%)
4 (5) 2 (3) .698
Age, y 46 6 14 49 6 15 .171
BMI, kg/m2 26 6 4 28 6 5 .031
Xanthomas, n (%)* 16 (23) 4 (16) .573
Xanthelasmas, n (%) - - -
Arcus cornealis, n (%)† 4 (6) 3 (14) .360
Active smoking, n (%) 8 (12) 5 (14) .757
Hypertension, n (%) 8 (10) 9 (19) .187
Diabetes, n (%) 0 6 (10) .003
Plasma lipids, mg/dL
Total cholesterol, mg/dL 391 6 69 383 6 84 .269
Triglycerides, mg/dL 88 (67–142) 115 (95–152) .339
HDL-C, mg/dL 59 6 18 51 6 14 .081
Liver panel
AST, U/L 26 (23–34) 26 (21–34) .729
ALT, U/L 33 (24–48) 31 (21–46) .804
g-GT, U/L - - -
Total bilirubin, mg/dL - - -
Other biochemical parameters
Creatinine kinase, U/L 118 (76–176) 123 (82–201) .952
Uric acid, mg/dL - - -
Glucose, mg/dL 99 6 10 102 6 15 .149
Insulin, mIU/L 9.7 (8.4–11) 8.6 (5.3–20) .272
HOMA-IR, U 2.2 (2.0–2.6) 2.1 (1.2–5.3) .155
Lipid medications
Statin use, n (%)‡ 58 (79) 35 (97) .014
PCSK9 mAbs use, n (%) 4 (5) 9 (15) .075
BMI, body mass index; LDL-C, low-density lipoprotein cholesterol; HDL-C, high-density lipoprotein cholesterol; AST, aspartate aminotransferase; ALT,
alanine aminotransferase; g-GT, gamma-glutamyltransferase; HOMA-IR, homeostatic model assessment; PCSK9 mAbs, proprotein convertase subtilisin
kexin type 9 monoclonal antibodies.
Data expressed as mean (6SD), median, and quartile range or as number (proportion) as appropriate. Lipid profile was measured before starting any
treatment. For continuous traits, P-value calculated by linear regression adjusted for age, gender, and BMI when appropriate. Non-normally distributed
values were log-transformed before entering the model. For categorical traits, P-value calculated by chi-square or by Fisher exact test as appropriate.
*Data on xanthomas available for N 5 93.
†Data on arcus cornealis available for N 5 88.
‡Data on statin use available for N 5 109.
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Supplementary Table 3 Characteristics of patients with FH from the Gothenburg cohort stratified by type of mutation
Trait
FH Gothenburg
P valueNonsense Missense
N 89 99
Women/men, n (%) 42/47 (47/53) 50/48 (51/49) .602
Homozygosity, compound heterozygosity or
double heterozygosity, n (%)
2 (2) 3 (3) .247
Age, y 44 6 14 47 6 15 .203
BMI, kg/m2 26 6 4 26 6 5 .958
Xanthomas, n (%)* 18 (35) 3 (6) ,.0001
Xanthelasmas, n (%) - - -
Arcus cornealis, n (%)† 5 (11) 3 (6) .477
Cardiovascular disease, n (%)k 26 (40) 35 (46) .471
Active smoking, n (%) 4 (7) 10 (17) .153
Hypertension, n (%) 11 (16) 8 (11) .382
Diabetes, n (%) 4 (6) 2 (3) .435
Plasma lipids, mg/dL
Total cholesterol, mg/dL 391 6 84 376 6 71 .020
Triglycerides, mg/dL 88 (71–124) 106 (77–150) .276
LDL-C, mg/dL 307 6 73 293 6 64 .009
HDL-C, mg/dL 54 6 15 56 6 17 .083
Treated LDL-C‡, mg/dL 142 6 75 139 6 64 .575
Lp(a), mg/dL 25 (10–53) 21 (10–53) .518
Liver panel
AST, U/L 28 (24–36) 26 (22–32) .443
ALT, U/L 34 (23–45) 29 (23–45) .557
g-GT, U/L - - -
Total bilirubin, mg/dL - - -
Other biochemical parameters
Creatinine kinase, U/L 124 (76–182) 109 (82–159) .562
Uric acid, mg/dL - - -
Glucose, mg/dL 99 6 13 101 6 10 .867
Insulin, mIU/L 9 (7.3–19.6) 9.4 (5.8–11.5) .247
HOMA-IR, U 2.3 (1.8–5.6) 2.2 (1.3–2.9) .596
Lipid medications
Statin use, n (%)x 61 (95) 44 (75) .001
PCSK9 mAbs use, n (%) 7 (8) 6 (6) .657
BMI, body mass index; LDL-C, low-density lipoprotein cholesterol; HDL-C, high-density lipoprotein cholesterol; AST, aspartate aminotransferase; ALT,
alanine aminotransferase; g-GT, gamma-glutamyltransferase; HOMA-IR, homeostatic model assessment; PCSK9 mAbs, proprotein convertase subtilisin
kexin type 9 monoclonal antibodies.
Data expressed as mean (6SD), median, and quartile range or as number (proportion) as appropriate. Lipid profile was measured before starting any
treatment. For continuous traits, P-value calculated by linear regression adjusted for age, gender, and BMI when appropriate. Non-normally distributed
values were log-transformed before entering the model. For categorical traits, P-value calculated by chi-square or by Fisher exact test as appropriate.
*Data on xanthomas available for N 5 93.
†Data on arcus cornealis available for N 5 88.
‡Treated LDL-C at last available assessment.
xData on statin use available for N 5 109.
kData available for N 5 65 (Nonsense) and N 5 76 (Missense).
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Supplementary Table 4 Characteristics of patients with FH stratified by center of recruitment
Trait FH Gothenburg FH CEGP Milan P-value
N 190 168
Women/men, n (%) 92/95 (49/51) 68/100 (40/60) .100
Homozygosity, compound heterozygosity or
double heterozygosity, n (%)
7 (3.7) 7 (4.2) .061
Age, y 46 6 15 39 6 17 ,.0001
BMI, kg/m2 26 6 4 24 6 4 .002
Xanthomas, n (%)* 21 (21) 95 (59) ,.0001
Xanthelasmas, n (%) - 14 (8) -
Arcus cornealis, n (%)† 8 (8) 44 (27) ,.0001
Cardiovascular disease, n (%)‡ 61 (43) 39 (23) ,.0001
Active smoking, n (%) 14 (7) 24 (14) ,.0001
Hypertension, n (%) 19 (10) 33 (20) .146
Diabetes, n (%) 6 (3) 7 (4) .996
Plasma lipids
Total cholesterol, mg/dL 383 6 78 394 6 85 .033
Triglycerides, mg/dL 79 (72–141) 114 (79–155) .184
LDL-C, mg/dL 299 6 68 316 6 82 .049
HDL-C, mg/dL 55 6 16 51 6 14 .488
Treated LDL-Cx, mg/dL 141 6 69 162 6 69 .023
Lp(a), mg/dL 24 (10–56) 21 (6–51) .003
Liver panel
AST, U/L 27 (22–34) 20 (17–26) ,.0001
ALT, U/L 32 (23–45) 20 (15–28) ,.0001
g-GT, U/L - 16 (12–25) -
Total bilirubin, mg/dL - 0.63 (0.44–0.93) -
Other biochemical parameters
Creatinine kinase, U/L 112 (76–170) 109 (75–164) .483
Uric acid, mg/dL - 4.9 6 1.3 -
Glucose, mg/dL 100 6 12 87 6 18 ,.0001
Insulin, mIU/L 9.2 (6.3–14) - -
HOMA-IR, U 2.2 (1.7–3.7) - -
Lipid medications
Statin use, n (%)k 105 (85) 92 (67) ,.0001
PCSK9 mAbs use, n (%) 13 (7) 26 (15) .001
BMI, body mass index; LDL-C, low-density lipoprotein cholesterol; HDL-C, high-density lipoprotein cholesterol; AST, aspartate aminotransferase; ALT,
alanine aminotransferase; g-GT, gamma-glutamyltransferase; HOMA-IR, homeostatic model assessment; PCSK9 mAbs, proprotein convertase subtilisin
kexin type 9 monoclonal antibodies.
Data are expressed as mean (6SD) or as number (proportion) as appropriate. Lipid profile was measured before starting any treatment. For continuous
traits, P-value calculated by linear regression adjusted for age, gender, and BMI when appropriate. Non-normally distributed values were log-transformed
before entering the model. For categorical traits, P-value calculated by chi-square or by Fisher exact test as appropriate.
*Data on xanthomas available for N 5 162 and N 5 101 for Milan and Gothenburg cohort, respectively.
†Data on arcus cornealis available for N 5 162 and N 5 95 for Milan and Gothenburg cohort, respectively.
‡Data on cardiovascular disease available for N 5 141 for Gothenburg cohort.
xTreated LDL-C at last available assessment.
kData on statin use available for N 5 140 and N 5 123 for Milan and Gothenburg cohort, respectively.
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Supplementary Table 5 Characteristics of patients with FH from the FH-CEGP Milan cohort stratified by cardiovascular disease status
Trait
FH CEGP Milan
P valueCVD negative CVD positive
N 129 39
Women/men, n (%) 60/69 (47/53) 8/31 (20/80) .003
Homozygosity, compound heterozygosity or
double heterozygosity, n (%)
4 (4) 2 (5) .999
Age, y 36 6 17 49 6 14 ,.0001
BMI, kg/m2 24 6 5 26 6 4 .021
Xanthomas, n (%)* 69 (56) 26 (67) .244
Xanthelasmas, n (%) 9 (7) 5 (13) .33
Arcus cornealis, n (%)† 27 (22) 17 (44) .008
Active smoking, n (%) 20 (16) 4 (10) .001
Hypertension, n (%) 20 (16) 13 (33) .019
Diabetes, n (%) 3 (2) 4 (10) .056
Plasma lipids, mg/dL
Total cholesterol, mg/dL 386 6 83 422 6 86 .257
Triglycerides, mg/dL 102 (76–147) 132 (112–197) .364
HDL-C, mg/dL 52 6 15 45 6 12 .029
Treated LDL-C, mg/dL‡ 168 6 60 143 6 87 .182
Liver panel
AST, U/L 20 (17–26) 21 (18–27) .934
ALT, U/L 19 (15–27) 24 (16–37) .939
g-GT, U/L 15 (12–22) 22 (15–29) .516
Total bilirubin, mg/dL 0.62 (0.43–0.94) 0.66 (0.49–0.83) .969
Other biochemical parameters
Creatinine kinase, U/L 109 (72–174) 110 (89–154) .184
Uric acid, mg/dL 4.7 6 1.3 5.3 6 1.4 .995
Glucose, mg/dL 85 6 13 95 6 28 .219
Insulin, mIU/L - - -
HOMA-IR, U - - -
Lipid medications
Statin use, n (%)x 71 (68) 21 (58) .281
PCSK9 mAbs use, n (%) 15 (12) 11 (28) .033
BMI, body mass index; LDL-C, low-density lipoprotein cholesterol; HDL-C, high-density lipoprotein cholesterol; AST, aspartate aminotransferase; ALT,
alanine aminotransferase; g-GT, gamma-glutamyltransferase; HOMA-IR, homeostatic model assessment; PCSK9 mAbs, proprotein convertase subtilisin
kexin type 9 monoclonal antibodies.
Data are expressed as mean (6SD), median, and quartile range or as number (proportion) as appropriate. Lipid profile was measured before starting
any treatment.
*Data on xanthomas available for N 5 162.
†Data on arcus cornealis available for N 5 162.
‡Treated LDL-C at last available assessment.
xData on statin use available for N 5 140.
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Supplementary Table 6 Characteristics of patients with FH from the FH-CEGP Milan cohort stratified by type of mutation
Trait
FH CEGP Milan
P valueNonsense Missense
N 85 78
Women/men, n (%) 38/49 (44/56) 30/49 (38/62) .457
Homozygosity, compound heterozygosity or
double heterozygosity, n (%)
2 (2) 5 (6) .259
Age, y 39 6 17 39 6 17 .990
BMI, kg/m2 24 6 4 24 6 5 .941
Xanthomas, n (%)* 49 (57) 44 (59) .752
Xanthelasmas, n (%) 7 (8) 7 (10) .749
Arcus cornealis, n (%)† 24 (28) 20 (27) .901
Cardiovascular disease, n (%) 24 (28) 15 (19) .209
Active smoking, n (%) 15 (18) 9 (12) .009
Hypertension, n (%) 17 (20) 14 (18) .770
Diabetes, n (%) 4 (5) 3 (4) .999
Plasma lipids, mg/dL
Total cholesterol, mg/dL 396 6 79 386 6 87 .395
Triglycerides, mg/dL 121 (83–167) 112 (78–141) .104
LDL-C, mg/dL 318 6 74 308 6 85 .411
HDL-C, mg/dL 50 6 13 52 6 16 .242
Treated LDL-C‡, mg/dL 159 6 71 164 6 67 .724
Lp(a), mg/dL 22 (7.3–57) 16 (5.0–47) .020
Liver panel
AST, U/L 19 (17–26) 21 (18–26) .224
ALT, U/L 18 (14–28) 20 (15–29) .331
g-GT, U/L 16 (13–26) 16 (12–24) .346
Total bilirubin, mg/dL 0.59 (0.42–0.93) 0.66 (0.49–0.93) .458
Other biochemical parameters
Creatinine kinase, U/L 108 (75–163) 110 (74–163) .922
Uric Acid, mg/dL 4.8 6 1.4 4.9 6 1.3 .456
Glucose, mg/dL 88 6 21 87 6 15 .761
Insulin, mIU/L - - -
HOMA-IR, U - - -
Lipid medications
Statin use, n (%)x 45 (64) 47 (69) .549
PCSK9 mAbs use, n (%) 16 (23) 8 (12) .087
BMI, body mass index; LDL-C, low-density lipoprotein cholesterol; HDL-C, high-density lipoprotein cholesterol; AST, aspartate aminotransferase; ALT,
alanine aminotransferase; g-GT, gamma-glutamyltransferase; HOMA-IR, homeostatic model assessment; PCSK9 mAbs, proprotein convertase subtilisin
kexin type 9 monoclonal antibodies.
Data are expressed as mean (6SD), median, and quartile range or as number (proportion) as appropriate. Lipid profile was measured before starting
any treatment.
*Data on xanthomas available for N 5 162.
†Data on Arcus cornealis available for N 5 162.
‡Treated LDL-C at last available assessment.
xData on statin use available for N 5 140.
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